Saul Yedgar
Corporate Officer/Principal en The Hebrew University of Jerusalem .
Perfil
Saul Yedgar is a Professor-Emeritus at The Hebrew University of Jerusalem, where he has been employed since 1982.
He previously worked as the Chief Scientific Officer at Celsus Therapeutics Plc from 2005 to 2011.
Prior to that, he held positions as a Principal at the National Institutes of Health and Institut Curie.
Yedgar received his undergraduate degree from Bar-Ilan University and his doctorate from The Hebrew University of Jerusalem in 1977.
Cargos activos de Saul Yedgar
| Empresas | Cargo | Inicio |
|---|---|---|
| The Hebrew University of Jerusalem | Corporate Officer/Principal | 01/01/1982 |
Antiguos cargos conocidos de Saul Yedgar.
| Empresas | Cargo | Fin |
|---|---|---|
Institut Curie
 Institut Curie Miscellaneous Commercial ServicesCommercial Services Institut Curie engages as a non-profit foundation. It operates a research center on biophysics, cell biology, and oncology and a hospital specialized in treatment of cancer. The company was founded in 1909 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Celsus Therapeutics Plc
 Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | - |
Formación de Saul Yedgar.
| The Hebrew University of Jerusalem | Doctorate Degree |
| Bar-Ilan University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
Celsus Therapeutics Plc
Celsus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Celsus Therapeutics Plc is a drug development company, which focuses on developing novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs and multi-functional anti-inflammatory drugs. The company main clinical candidates are MRX-5, MRX-6, MRX-4, CFX-1 and OPX-1. Celsus Therapeutics was founded on October 7, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Institut Curie
Institut Curie Miscellaneous Commercial ServicesCommercial Services Institut Curie engages as a non-profit foundation. It operates a research center on biophysics, cell biology, and oncology and a hospital specialized in treatment of cancer. The company was founded in 1909 and is headquartered in Paris, France. | Commercial Services |
- Bolsa de valores
- Insiders
- Saul Yedgar
